DRD2 and neoplasm: Furthermore, we speculate that D2R agonist treatment may reduce immunosuppression within the tumour microenvironment, based upon our prior studies demonstrating that D2R agonist treatment reduces tumour-infiltrating myeloid-derived suppressor cells in NSCLC [60].